Answers are grounded in this paper and cite their sources.
In patients with acromegaly, chronic excess of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) leads to the development of acromegalic cardiomyopathy. Its main features are biventricular hypertrophy, diastolic dysfunction, and in later stages, systolic dysfunction and congestive heart failure. Surgical and/or pharmacological treatment of acromegaly and control of cardiovascular risk factors help reverse some of these pathophysiologic changes and decrease the high risk of cardiovascular complications.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: